Neurocrine Biosciences presents a new analysis that benchmarks clinically meaningful change in general health reported by patients with tardive dyskinesia. Company announcement - FT.com.
Neurocrine Biosciences presents a new analysis that benchmarks clinically meaningful change in general health reported by patients with tardive dyskinesia. Company announcement - FT.com.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in